Eradication of Candida auris biofilm in vitro by a polygalacturonic and caprylic acid wound ointment

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2024-11-05 DOI:10.1016/j.mycmed.2024.101519

Y-Lan Truong, Joel Rosenblatt, Bahgat Gerges, Ying Jiang, Issam Raad

{"title":"Eradication of Candida auris biofilm in vitro by a polygalacturonic and caprylic acid wound ointment","authors":"Y-Lan Truong, Joel Rosenblatt, Bahgat Gerges, Ying Jiang, Issam Raad","doi":"10.1016/j.mycmed.2024.101519","DOIUrl":null,"url":null,"abstract":"<div><div>Candida auris is a rapidly spreading virulent pathogen frequently resistant to multiple antifungal drugs that can form biofilms and infect wounds. Hence, there is a need for C. auris wound treatments not posing risks for developing antifungal resistance. We tested the ability of a polygalacturonic and caprylic acid ointment (PG+CAP) to rapidly eradicate C. auris biofilms within 2-hour exposures in an in vitro model. Medical-grade honey (MediHoney) wound ointment was used as a comparator. Nine different C. auris strains were tested. PG+CAP eradicated biofilms of 8 of the 9 tested strains and produced a > 5-log10 reduction of the ninth. MediHoney produced reductions ranging from 2 to 4 log10 without fully eradicating any strains. The differences between PG+CAP and MediHoney were statistically significant (p < 0.05). These results suggest that PG+CAP is a promising antimicrobial ointment warranting further in vivo study in wounds which may be colonized by C. auris biofilms.</div></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 4","pages":"Article 101519"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S115652332400060X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Candida auris is a rapidly spreading virulent pathogen frequently resistant to multiple antifungal drugs that can form biofilms and infect wounds. Hence, there is a need for C. auris wound treatments not posing risks for developing antifungal resistance. We tested the ability of a polygalacturonic and caprylic acid ointment (PG+CAP) to rapidly eradicate C. auris biofilms within 2-hour exposures in an in vitro model. Medical-grade honey (MediHoney) wound ointment was used as a comparator. Nine different C. auris strains were tested. PG+CAP eradicated biofilms of 8 of the 9 tested strains and produced a > 5-log₁₀ reduction of the ninth. MediHoney produced reductions ranging from 2 to 4 log₁₀ without fully eradicating any strains. The differences between PG+CAP and MediHoney were statistically significant (p < 0.05). These results suggest that PG+CAP is a promising antimicrobial ointment warranting further in vivo study in wounds which may be colonized by C. auris biofilms.

查看原文本刊更多论文

聚半乳糖醛酸和辛酸伤口软膏在体外根除念珠菌生物膜。

念珠菌是一种传播迅速的烈性病原体，经常对多种抗真菌药物产生抗药性，可形成生物膜并感染伤口。因此，需要一种不会产生抗真菌抗药性风险的念珠菌伤口治疗方法。我们在体外模型中测试了聚半乳糖醛酸和辛酸软膏（PG+CAP）在 2 小时暴露时间内快速消灭蛔虫生物膜的能力。医用级蜂蜜（MediHoney）伤口软膏作为对比药。测试了九种不同的 C. auris 菌株。PG+CAP 根除了 9 种测试菌株中 8 种菌株的生物膜，并使第 9 种菌株的生物膜减少 > 5-log10。MediHoney 能减少 2 到 4 log10 的菌株，但不能完全根除任何菌株。PG+CAP 和 MediHoney 之间的差异具有统计学意义（p < 0.05）。这些结果表明，PG+CAP 是一种很有前景的抗菌软膏，值得在可能有肛门脓疱疮杆菌生物膜定植的伤口中进一步进行体内研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.